HEALTHCAP VIII ADVISOR AB
HEALTHCAP VIII ADVISOR AB is a Seed, Series A and Series C+ fund in the US, Europe and Nordics writing $10M–$50M checks into biotechnology, precision-medicine, therapeutics and healthcare-tech.
- Stages
- Seed, Series A, Series C+
- Sectors
- biotechnology, precision-medicine, therapeutics, healthcare-tech
- Check size
- $10M–$50M
- Invests in
- US-wide, Europe, Nordics
- Round role
- Leads rounds
- Actively investing
- Yes
- Founded
- 1996
- Assets under management
- 1B+
Thesis
HealthCap VIII Advisor AB, part of the HealthCap umbrella, is a European venture capital firm founded in 1996, focusing on the life sciences sector. Their investment strategy centers on identifying and backing companies with transformative potential in therapeutics, particularly in biotechnology and precision medicine, addressing diseases with high unmet medical needs. While their primary geographic focus is Europe, they also consider global opportunities, with a notable presence in the Nordic region and the United States. HealthCap typically invests across various stages, from early-stage venture to growth-stage investments, and has a history of leading investment rounds. HealthCap VIII, established in 2019, had a final close of EUR 232 million, making it the firm's largest fund. As of 2023, HealthCap has committed capital exceeding EUR 1 billion across its funds. Their typical deal range is between $10 million and $50 million.
Common questions
Does HEALTHCAP VIII ADVISOR AB invest at the Seed stage?
Yes. HEALTHCAP VIII ADVISOR AB lists Seed, Series A and Series C+ among the stages it invests in.
What check size does HEALTHCAP VIII ADVISOR AB write?
HEALTHCAP VIII ADVISOR AB writes $10M–$50M checks.
Where does HEALTHCAP VIII ADVISOR AB invest?
HEALTHCAP VIII ADVISOR AB invests in the US, Europe and Nordics.